• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Acumen Pharmaceuticals Inc (NQ: ABOS )

    2.870 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 2.870
    Bid (Size) 2.670 (1)
    Ask (Size) 4.590 (2)
    Prev. Close 2.870
    Today's Range 2.870 - 2.870
    52wk Range 1.810 - 7.620
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Trading SMID Biotech Stocks In A Volatile Market
    Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
    Via Talk Markets

    Performance

    YTD
    -32.15%
    -32.15%
    1 Month
    +24.24%
    +24.24%
    3 Month
    -8.31%
    -8.31%
    6 Month
    -15.34%
    -15.34%
    1 Year
    -58.22%
    -58.22%

    More News

    Read More
    ABOS Stock Earnings: Acumen Pharmaceuticals Beats EPS for Q1 2024
    Via InvestorPlace
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Acumen Pharmaceuticals's Earnings: A Preview
    Via Benzinga
    Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q4 2023
    Via InvestorPlace
    Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Earnings Scheduled For March 26, 2024
    Via Benzinga
    Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot
    Via InvestorPlace
    3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom
    Via InvestorPlace
    Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Are You A Trader Or Investor: Biotech Momentum Is Picking Up
    Via Talk Markets
    Topics ETFs
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.